Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Immune Thrombocytopenia (ITP) Clinical Trial

Official title:

Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06371417
• Other study ID #: RAY902CT
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: May 31, 2024
• Est. completion date: June 30, 2026

Study information

• Verified date: April 2024
• Source: Chugai Pharmaceutical
• Contact: Clinical trials information
• Phone: only use Email
• Email: clinical-trials[@]chugai-pharm.co.jp
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 144
• Est. completion date: June 30, 2026
• Est. primary completion date: June 30, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent form

2. Age >= 18 and <=75 at the time of signing informed consent form (except for BP; Age >=18 and <= 85 with Karnofsky score >= 60% at screening)

3. Ability to comply with the study protocol

4. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use highly effective contraceptive methods

5. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm

6. APS cohort: Established primary APS defined by the following criteria (at least one of the laboratory criteria and one of the clinical criteria must be met):

• Laboratory criteria (aPL profile)

• Persistently positive lupus anticoagulant (LA) test

• Persistently positive anticardiolipin (aCL) immunoglobulin G (IgG) isotype

• Persistently positive anti-beta-2 glycoprotein-1 (aß2GPI) IgG isotype

• Clinical criteria

• Livedoid vasculopathy and presence of skin ulcer

• Acute/chronic aPL nephropathy

7. BP cohort:

• 1) Age >= 18 and <= 85 with Karnofsky score >= 60 %

• 2) Predominant cutaneous lesions

• 3) Diagnosis with BP with following assessments positive:

• a Positive direct immunofluorescence, and either

• b Positive indirect immunofluorescence, or

• c Positive serology on ELISA for BP180 autoantibody

• 4) Bullous Pemphigoid Disease Area Index (BPDAI) score >= 20

• 5) Weekly average of daily Peak Pruritus Numerical Rating Score (PP-NRS) >=4

• 6) Accept to take photograph of bullous lesions

8. BS cohort:

• 1) Diagnosed with BS

• 2) Oral ulcers that occurred at least 3 times in the previous 12 month period

• 3) Have at least 2 oral ulcers over the 4 weeks prior to screening

• 4) Have at least 2 oral ulcers at Week 0

• 5) Have prior treatment with at least 1 non-biologic BS therapy

• 6) Patients who need systemic therapy as whose oral or mucocutaneous ulcers cannot be adequately controlled by topical therapy

9. DM cohort:

• 1) Diagnosed with definite or probable inflammatory myopathies and categorized as DM

• 2) Patients with inadequate response to corticosteroids and/or immune-suppressants or intolerance to DM therapies

• 3) Manual Muscle Test-8 (MMT-8) score < 142, with at least one abnormality in the following Core Set Measures:

• Patient Global Activity Visual Analogue Scale (PtGA-VAS) >= 2 cm

• Physician Global Activity Visual Analogue Scale (PhGA-VAS) >= 2 cm

• Global extra-muscular activity >= 2 cm

• At least one muscle enzyme > 1.5 times upper limit of normal (ULN)

• Health Assessment Questionnaire (HAQ) >= 0.25

• 4) Moderate to severe DM defined as CDASI activity score > 14

10. IMNM cohort:

• 1) Clinically Diagnosed with IMNM as anti-HMGCR myopathy or anti-SRP myopathy

• 2) Creatine kinase (CK) > 1,000 U/L

• 3) Patients who have an inadequate response to corticosteroids and/or immunosuppressants or intolerance to IMNM therapies

• 4) MMT-8 score < 142

11. ITP cohort:

• 1) Confirmed diagnosis of persistent/chronic ITP based on the following criteria:

• ITP defined per the current guidelines

• Platelet count <= 30 × 10^9/L on 2 consecutive occasions

• 2) Lack of an sustained adequate platelet count response to a thrombopoietin receptor agonist and at least one other ITP treatment or a second thrombopoietin receptor agonist (TPO-RA)

• 3) A history of response with an platelet counts increase more than 20 × 10^9/L from baseline by at least one prior line of therapy

Exclusion Criteria:

1. History of anaphylaxis or hypersensitivity to a biologic agent

2. Active infection requiring systemic antiviral, antibiotics or antifungal

3. Planned surgery during the study

4. Pregnant or breastfeeding, or intending to become pregnant

5. Any serious medical condition or abnormality in clinical laboratory tests that precludes the patient's safe participation in and completion of the study

6. Clinically significant ECG abnormalities

7. Illicit drug or alcohol abuse

8. Clinical diagnosis of autoimmune diseases other than the target disease (except for Sjögren's syndrome in DM and IMNM)

9. Positive for hepatitis B surface antigen

10. Positive for hepatitis C virus antibody

11. Positive for human immunodeficiency virus antibody

12. Evidence of current infection with tuberculosis

13. History of cancer within 5 years

14. Treatment with investigational therapy within 28 days or 5 half-lives

15. Previous and current treatment with anti-C1s antibody at any time

16. Other complement inhibitors within 3 months

17. Patients who receive any treatments which fall into the Prohibited Therapy Criteria

18. Patients with an elevated alanine aminotransferase or aspartate aminotransferase > 1.5 × ULN in combination with an elevated total bilirubin > 1.5 × ULN

19. APS cohort:

• 1) APS associated with other systemic autoimmune disease

• 2) Acute thrombosis (arterial or venous acute thrombosis diagnosis) within 30 days before screening

• 3) Patients with thrombotic APS without any anticoagulation treatment

• 4) Treatment with prohibited medications

20. BP cohort:

• 1) Initiation of treatment with or increase in the dose of systemic or topical corticosteroid within 2 weeks

• 2) Current treatment with a drug that may cause or exacerbate BP unless the dose has been stable

• 3) Initiation of treatment with topical calcineurin inhibitor, or topical phosphodiesterase (PDE) 4 inhibitor within 7 days

• 4) Treatment with prohibited medications

21. BS cohort:

• 1) BS-related active major organ involvement-ocular lesions requiring immunosuppressive therapy, pulmonary (e.g., pulmonary artery aneurysm), vascular (e.g., thrombophlebitis), gastrointestinal (e.g., ulcers along the gastrointestinal tract), and central nervous systems (e.g., meningoencephalitis) manifestations

• 2) History of venous or arterial thrombosis within 1 year

• 3) Treatment with prohibited medications

22. DM cohort:

• 1) PhGA-VAS improvement >= 3, or clinically relevant improvement between screening and baseline

• 2) Overlap myositis (except for overlap with Sjögren's syndrome), connective tissue disease associated DM, inclusion body myositis, polymyositis, IMNM, juvenile DM or drug-induced myopathy

• 3) Cancer-associated myositis

• 4) Significant muscle damage

• 5) Past history of severe Interstitial lung disease flare, severe non-infectious lung inflammation which required active intervention, or multiple episodes of lung disease

• 6) Severe respiratory muscle weakness

• 7) Severe bulbar palsy

• 8) Treatment with prohibited medications

23. IMNM cohort:

• 1) PhGA-VAS improvement >= 3, or clinically relevant improvement between screening and baseline

• 2) Overlap myositis (except for overlap with Sjögren's syndrome), connective tissue disease associated DM, inclusion body myositis, polymyositis, juvenile DM or druginduced myopathy

• 3) Cancer-associated myositis

• 4) Significant muscle damage

• 5) Past history of severe Interstitial lung disease (ILD) flare, severe non-infectious lung inflammation which required active intervention, or multiple episodes of lung disease

• 6) Severe respiratory muscle weakness

• 7) Severe bulbar palsy

• 8) Treatment with prohibited medications

24. ITP cohort:

• 1) Secondary ITP

• 2) Clinical diagnosis or history of Myelodysplastic Syndrome or autoimmune hemolytic anemia

• 3) History of venous or arterial thrombosis within 12 months

• 4) Patients who experienced major bleeding within 4 weeks

• 5) Treatment with prohibited medications

• 6) Any laboratory test results meet either of the following criteria at screening:

• Hemoglobin <10 g/dL

• Thyroid-stimulating hormone >= 10 µIU/mL

Related Conditions & MeSH terms

• Antiphospholipid Syndrome
• Antiphospholipid Syndrome (APS)
• Behcet Syndrome
• Bullous Pemphigoid (BP)
• Dermatomyositis
• Dermatomyositis (DM)
• Immune System Diseases
• Immune Thrombocytopenia (ITP)
• Pemphigoid, Bullous
• Purpura, Thrombocytopenic, Idiopathic
• Syndrome
• Thrombocytopenia

Intervention

Drug:
• RAY121
Injection

Locations

Country	Name	City	State
Japan	Hamamatsu University Hospital	Hamamatsu	Shizuoka
Japan	Toho University Omori Medical Center	Ota-ku	Tokyo
Japan	Hokkaido University Hospital	Sapporo	Hokkaido
Japan	Tohoku University Hospital	Sendai	Miyagi
Japan	Osaka University Hospital	Suita	Osaka
United States	Oregon Health & Science University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Chugai Pharmaceutical

Countries where clinical trial is conducted

United States,  Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events (AEs)	Incidence, severity, and causal relationship of AEs	Baseline to Week 32
Secondary	RAY121 concentration	Serum RAY121 concentration	Baseline to Week 32
Secondary	AUCt	Area under the concentration-time curve over a dosing interval (AUCt)	Baseline to Week 32
Secondary	Cmax	Maximum observed serum concentration (Cmax)	Baseline to Week 32
Secondary	Cmin	Minimum observed serum concentration (Cmin)	Baseline to Week 32
Secondary	Active C1s	Active C1s	Baseline to Week 32
Secondary	Total C1s	Total C1s	Baseline to Week 32
Secondary	Complement activity (classical pathway)	Complement activity (classical pathway)	Baseline to Week 32
Secondary	Anti-RAY121 antibodies	Titer of anti-RAY121 antibodies	Baseline to Week 32